

DAFTAR PUSTAKA

1. Rosai J, Albores SJ, Asioli S, Baloch ZW, Bogdanova T, Chen H *et al.* Papillary thyroid carcinoma in : World Health Organization Classification of Tumours Pathology & Genetics Tumours of Endocrine Organs. Lyon. 2017. pp : 81-10.
2. Rosai J, Talini G. Thyroid gland. In : Rosai and Ackerman's Surgical Pathology. Tenth Edition. New York. USA. 2011. pp : 487-28.
3. Scheider DF, Chen H.. New Developments In The Diagnosis And Treatment Of Thyroid Cancer. Section of Endocrine Surgery, *CA Cancer J Clin.* 2013. Vol.63, No.6, pp. 373–21.
4. Badan Registrasi Kanker Perhimpunan Dokter Spesialis Patologi Indonesia 2014. Kanker di Indonesia tahun 2014 : Data Histopatologik. 2014. Jakarta Direktorat Jendral Pelayanan Medik Kementerian Kesehatan RI, Yayasan Kanker Indonesia, Jakarta.
5. Achmad D, Sebastian J, Hernowo BS, Rizki KA. Ekspresi BRAF Mutan pada Karsinoma Tiroid Papiler yang Bermetastase ke Kelenjar Getah Bening Regional. *MKB.* 2013. Vol 45. No 4
6. Davies L, Morris L, Haymart M, Chen AY, Goldenberg D, Morris J, Ogilvie JB *et al.* American Association of Clinical Endocrinologists and American College Of Endocrinology Disease State Clinical Review : The Increasing Incidence of Thyroid Cancer, Boston. *Endocrine Practice.* 2015. Vol.21, No.6, pp. 686-10.
7. Putri E, Khambri D, Renita SR. Hubungan Daerah Tempat Tinggal dengan Gambaran Histopatologi Karsinoma Tiroid pada Masyarakat Sumatera Barat *Jurnal Kesehatan Andalas.* 2014. Vol. 3. No. 2
8. Fletcher DM. Tumors of Thyroid and Parathyroid Gland. In : Diagnostic Histopathology of Tumor. 4th. Philadelphia. Elsevier. 2013.
9. Czarniecka A, Oczko-Wojciechowska M, Barczynski, M. BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrence. *Gland Surg.* 2016. Vol. 5. No. 5. pp. 495-10.
10. Ritterhouse L.L, Barletta J.A. BRAF V600E mutation-specific antibody: A review. *Semin Diagn Pathol.* 2015. Vol. 32, No. 5. pp. 400-8.
11. Tang K.T, Lee, C.H. BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications. *J Chin Med Assoc.* 2010. Vol. 73, No. 3. pp. 113-28.

12. Song YS, Lim JA, Park YJ. Mutation profile of well-differentiated thyroid cancer in Asians. Seoul. *Endocrinol Metab.* 2015. Vol.30, No.3. pp. 252-62.
13. Sun J, Zhang J, Lu J, Gao J, Lu T, Ren X, Duan H, *et al.* Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma. *Int J Clin Exp Pathol.* 2015. Vol. 8, No. 11. pp. 15072-78.
14. Rusmana MP, Sriwidayani NP, Dewi IGA. BRAF V600E expression found in aggressive papillary thyroid carcinoma (PTC), lymph node metastasis, and extra-thyroid extension. Lecturer of Anatomic Pathology. Bali. *Bali Medical Journal (Bali Med J).* 2018. Vol.7, No. 3. pp. 658-4.
15. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, *et al.* 2015 american thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. *Thyroid.* 2016. Vol. 26, No.1. pp. 1-133.
16. Kuo CY, Liu TP, Yang PS, Cheng SP. Characteristics of lymphocyte-infiltrating papillary thyroid cancer. *Journal of Cancer Research and Practice.* 2017. Vol.4. pp. 95-4.
17. Villagelin, Santosa RB, Romaldini JH. Is diffuse and peritumoral lymphocyte infiltration in papillary thyroid cancer a marker of good prognosis ?. [*J Endocrinol Invest.*](#) 2011. Vol. 34. pp.403-5.
18. Yeo MK, Bae JS, Lee S, Kim MH, Lim DJ, Lee YS, Jung CK. A comparison with classic type in the patients with coexisting Hashimoto's Thyroiditis. [*Int J Endocrinol.*](#) 2014. pp. 301-747.
19. Kim WW, Ha TK, Bae SK. Original Research Article Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis. [*Journal of Otolaryngology - Head & Neck Surgery.*](#) 2018. Vol. 47. pp. 4.
20. Ilie MI, Lassalle s, Long-Mira E, Bonnetaud C, Bordone O, Lespinet V, Lamy A, *et al.* Diagnostic value of immunochemistry for the detection of the BRAF (V600E) mutation in papillary thyroid carcinoma : comparative analysis with three DNA-based assay. *Thyroid.* 2014. Vol. 24. No.5. pp. 858-66.
21. Liu Y, Su L, Xiao H. Review of Factors Related to the Thyroid Cancer Epidemic. *International Journal of Endocrinology.* China. 2017.
22. Thomson LD, Wenig BM, Muller S, Nelson B. Papillary Thyroid Carcinoma. In : *Diagnostic Pathology Head and Neck.* 2th. Philadelphia. Elsevier. 2016. pp 988-18.

23. Kumar V, Abbas AK, Aster JC. Endocrine System. In : Robbin and Cottran : Pathologic Basic of Disease. 9th Ed. Philadelphia : Elsevier Saunders. 2015. pp 715-50.
24. Delellis RA, Williams ED. WHO Classification of Tumours of Endocrine Organs Fourth Edition. 4th ed. Delellis RA, Lyoyd RV, Heitz PU, Eng C. Lyon : IARC Press, 2017. p 51-5.
25. Xing M. Molecular pathogenesis and mechanism of thyroid cancer. Laboratory for Cellular and Molecular Thyroid Research, [Nat Rev Cancer](#). USA. 2013. Vol. 13. No. 3. pp.184-15.
26. Younis E. Oncogenesis of Thyroid Cancer. Asian Pac J Cancer. 2017. Vol 18. No. 5. pp. 1191-8.
27. Loretta LY, Chan JK. Thyroid and Parathyroid. In : Weidner N, Cote JR, Suster S, Weiss LM. 2009. Modern Surgical Pathology. 2nd . Philadelphia. Elsevier. 2009. pp 1597-89.
28. Wang X, Cheng W, Liu C, Li J. Tall cell variant of papillary thyroid carcinoma : current evidence on clinicopathologic features and molecular biology. [Oncotarget](#). 2016. Vol. 7. No. 26. pp 40792-7.
29. Lloyd RV, Buehler D, Khanafshar E. Papillary Thyroid Carcinoma Variants. ISRN Oncology. 2011. Vol. 5, pp. 51-5.
30. Rahbari R, Zhang L, Kebebew E. Thyroid cancer gender disparity. [Future Oncol](#). 2010. Vol. 6. No. 11. Pp. 1771-9.
31. Ozata M, Aksu A, Narin Y, Finci R, Bayhan H, Ozdemi C. The Relationship Between Lymphocytic Infiltration in the Thyroid Gland and Tumor Recurrence in Papillary Thyroid Carcinoma. Turkish Journal of Endocrinology and Metabolism. 1999. Vol.3. pp. 113-11.
32. Kebebew E, Treseler PA, Philip, Ituarte, Clark OH. Coexisting Chronic Lymphocytic Thyroiditis and Papillary Thyroid Cancer Revisited. [World J Surg](#). 2001. Vol 25. No. 5. pp. 632-7.
33. Roman S, Sosa JA. Aggressive variants of papillary thyroid cancer. [Adv Anat Pathol](#). 2012. Vol. 25. No.3. pp. 172-7.
34. Wazen RM, Kuroda S, Nishio C, Sellin K, Brunski JB, Nanci A. Long-term tren of thyroid cancer risk among Japanese atomic-bomb survivors : 60 years after exposure. *Int J Cancer*. 2014. Vol. 8. No. 9. pp.1385-95.

35. Vivero M, Kraft S, Barletta JA. Risk Stratification of Follicular Variant of Papillary Thyroid Carcinoma. In : Thyroid Cancer and Nodul. 2013. Vol 23. No.3. pp. 273-5.
36. Aghajani MJ, Yang T, Charles E, Graham S, Wu X, Niles N. Predictive relevance of programmed cell death protein 1 and tumor-infiltrating lymphocyte expression in papillary thyroid cancer. *Surgery*. 2017. Vol. 163. No. 1. pp. 130-6.
37. Omur, Baran, Y. An update on molecular biology of thyroid cancers. *Crit Rev Oncol Hematol*. 2014. Vol. 90. No. 3. pp. 233-52.
38. Li DD, Zhang YF, Xu HX, Zhang XP. The role of BRAF in the pathogenesis of thyroid carcinoma. *Front Biosci*. 2015. Vol. 20. pp. 1068-78.
39. Fagin J A, Mitsiades N. Molecular pathology of thyroid cancer : diagnostic and clinical implications. *Best Pract Res Clin Endocrinol Metab*. 2008. Vol. 22. No. 6. pp. 955-69.
40. Xing M. Prognostic utility of BRAF mutation in papillary thyroid cancer. *Mol Cell Endocrinol*. 2010. Vol. 321. No. 1. pp. 86-7.
41. Daliri M, Abbaszadegan M R, Bahar M M, Arabi A, Yadollahi M, Ghafari A, Taghehchian N, *et al*. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study. *Endocr Res*. 2014. Vol. 39. No. 4. pp. 189-93.
42. Fisher K E, Neill S G, Ehsani L, Caltharp S A, Siddiqui M T, Cohen C. Immunohistochemical Investigation of BRAF p.V600E mutations in thyroid carcinoma using 2 separate BRAF antibodies. *Appl Immunohistochem Mol Morphol*. 2014. Vol. 22. No. 8. pp. 562-7.
43. Ries L, Melbert D, Krapcho M. editors. SEER cancer statistics review, 1975-2005. Bethesda, MD: National Cancer Institute;. Available at: http://seer.cancer.gov/csr/1975_2005/. 2008.
44. Jonklaas J, Nogueras-Gonzalez G, Munsell M, Litofsky D, Ain KB, Brierley JD, Cooper DS *et al*. The Impact of Age and Gender on Papillary Thyroid Cancer Survival. 2012. Vol. 97. No. 6. pp : E878 –9.
45. Shi X, Liu R, Basolo F, Glannini, Shen X, Teng D, Guan H *et al*. Differential Clinicopathological Risk dan Prognosis of Major Papillary Thyroid Cancer Variant. 2015.
46. Cho JS, Yoon JH, Park MH, Shin SH, Jegal YJ, Lee JS, Kim HK. Age and prognosis of papillary thyroid carcinoma: retrospective stratification into three groups. 2012. Vol. 83. pp : 259-266.

47. Ying AK, Huh W, Bottomley S, Evans DB, Waguespack SG. Thyroid Cancer in Young Adults. *Seminars in Oncology*. 2009. Vol 36, No. 3, pp : 258-274.
48. Filipovic A, Vuckovic L. Lymphocytic infiltration as a prognostic factor in papillary thyroid carcinoma. 2017.
49. Park AY, Son EJ, Kim JA, Youk JH, Park YJ, Park CS, Chang HS. Association of the BRAFV600E Mutation with Sonographic Feature and Clinicopathologic Characteristics in a Large Population with Conventional Papillary Thyroid Carcinoma. www.plosone.org. 2014. Vol. 9, No. 10.
50. Falchook GS, Millward M, Hong D, Naing A, Paul SP, Waguespack SG, Cabanillas ME *et al*. BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF-Mutant Thyroid Cancer. *Thyroid*. 2015. Vol. 25. No 1.
51. Zagzag J, Pollack A, Dultz L, Dhar S, Ogilvie JB, Heller KS, Deng FM, *et al*. Clinical utility of immunohistochemistry for the detection of the BRAFV600E mutation in papillary thyroid carcinoma. *Surgery*. 2013. Vol 154. No. 6. pp : 1199-204.
52. Ming J, Liu Z, Zeng W, Maimaiti Y, Guo Y, Nie X, Chen C *et al*. Association between BRAF and RAS mutations, and RET rearrangements and the clinical feature of papillary thyroid cancer. *Int J Clin Exp Pathol*. 2015. Vol. 8. No. 11. pp. 15155-15162.
53. Min HS, Lee C, Jung KC. 2013. Correlation of Immunohistochemical Marker and BRAF Mutation Status with Histological Variant of Papillary Thyroid Carcinoma in The Korean Population. *J Korean Med Sci*. Vol. 28. Pp. 534-541.
54. Finkelstein A, Levy GH, Hui P, Prasad A, Virk R, Chieng DC, Roman SA, *et al*. 2012. Papillary thyroid carcinoma with and without BRAFV600E mutations are morphologically distinct. *Histopathology*. Vol 60. No. 7. Pp : 1052-8.
55. Li C, Lee KC, Schneider EB, Zeiger MA. 2012. BRAFV600E mutation and Its Association with Clinicopathological Feature of Papillary Thyroid Cancer : A Meta-Analysis. *J Clin Endocrinol Metab*. Vol 97. No. 12. Pp.4559-4570.
56. Mckelvie, Chan F, Yu, Waring P, Gresshoff I, Farrell S, Williams RA. 2014. The prognostic significance of the BRAF V600E mutation in papillary thyroid carcinoma detected by mutation-specific immunohistochemistry. *Pathology*. Vol 46. No 6.
57. Shen X, Zhu G, Liu R, Viola D, Elisei R, Puxeddu E, Fugazzola L *et al*. 2018. Patient Age Associated Mortality Risk Is Differentiated by

BRAFV600E Status in Papillary Thyroid Cancer. *J Clin Oncol.* Vol 10.No 5. Pp. 438-445.

58. Ward LS. 2014. Immune Response in Thyroid Cancer : Widening the Boundaries. *Scientifica.* pp. 25450- 20.
59. Marotta V, Guerrat A, Zatelli MC, Uberti ED, Stasit VD, Faggiano A, Colao A *et al.* 2013. BRAF mutation positive papillary thyroid carcinoma is less advanced when Hashimoto's thyroiditis lymphocytic infiltration is present. *Clinical Endocrinology.* Vol. 79. Pp 733-738.
60. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer : the next generation. *Cell.* Vol. 144. Pp 646-674.

